Mihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, Luigi Cerbone, Casilda Llacer, Kira-Lee Koster, Guilhem Roubaud, Ugo De Giorgi, Florence Joly, François Cherifi, Adrien Rochand, Aurelius Omlin, Himisha Beltran, Rafael Morales-Barrera, Mylene Annonay, Diletta Bianchini, Johann de Bono, Elena Castro, Giulia Baciarello, Silke Gillessen, Antoine Thiery-Vuillemin, Karim Fizazi
{"title":"Activity of Platinum Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer and DNA Damage Repair Gene Alterations.","authors":"Mihaela Aldea, Emeline Orillard, Alice Bernard-Tessier, Luigi Cerbone, Casilda Llacer, Kira-Lee Koster, Guilhem Roubaud, Ugo De Giorgi, Florence Joly, François Cherifi, Adrien Rochand, Aurelius Omlin, Himisha Beltran, Rafael Morales-Barrera, Mylene Annonay, Diletta Bianchini, Johann de Bono, Elena Castro, Giulia Baciarello, Silke Gillessen, Antoine Thiery-Vuillemin, Karim Fizazi","doi":"10.1200/PO-25-00310","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in <i>BRCA2</i>. PARP inhibitors (PARPi) are standard treatments for <i>BRCA1/2</i>-altered patients with mCRPC, and evidence for platinum agents is limited. This study assesses single-agent platinum therapy in patients with mCRPC with and without DDR alterations.</p><p><strong>Methods: </strong>This multicenter, retrospective study included patients with mCRPC with known DDR status treated with platinum monotherapy. DDR-positive (DDR+) patients had deleterious germline or somatic alterations in DDR genes (<i>BRCA1</i>, <i>BRCA2</i>, <i>CDK12</i>, <i>ATM</i>, <i>CHEK2</i>, <i>PALB2</i>, or <i>FANCA</i>), whereas DDR-negative (DDR-) patients had no such alterations. Prostate-specific antigen (PSA) response, progression-free survival (PFS, PSA/clinical/radiographic), and overall survival (OS) were assessed in DDR+ and DDR- groups.</p><p><strong>Results: </strong>Among 129 patients, 81 had DDR+ and 48 had DDR- cancers. A PSA decline of ≥50% was demonstrated in 48% in BRCA, 9% in DDR+ non-BRCA, and 13% in DDR- patients (<i>P</i> < .0001). Objective responses occurred in 37.5% in BRCA, 11% in DDR+ non-BRCA, and 13% in DDR- patients (<i>P</i> = .017). No response was reported in DDR+ patients who had received previous PARPi (n = 16). The median PSA response was 5 months for BRCA, 2 months for DDR+ non-BRCA, and 1.7 months for DDR- patients, respectively (<i>P</i> = .015), whereas the median clinical/radiographic PFS was 4.7 months, 2.8 months, and 2 months, respectively (<i>P</i> = .2). In PARPi-naïve patients, the median OS was 13.7 months for BRCA, 8.7 months for DDR+ non-BRCA, and 6.1 months for DDR- patients (<i>P</i> = .013).</p><p><strong>Conclusion: </strong>Single-agent platinum agents show significant anticancer activity in <i>BRCA</i>-mutated patients with mCRPC without previous PARPi exposure. With their low cost and broad availability, platinum agents offer a practical alternative, particularly in regions where PARPi are inaccessible.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"9 ","pages":"e2500310"},"PeriodicalIF":5.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO-25-00310","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Up to 30% of patients with metastatic castration-resistant prostate cancer (mCRPC) have DNA damage repair (DDR) gene alterations, mainly in BRCA2. PARP inhibitors (PARPi) are standard treatments for BRCA1/2-altered patients with mCRPC, and evidence for platinum agents is limited. This study assesses single-agent platinum therapy in patients with mCRPC with and without DDR alterations.
Methods: This multicenter, retrospective study included patients with mCRPC with known DDR status treated with platinum monotherapy. DDR-positive (DDR+) patients had deleterious germline or somatic alterations in DDR genes (BRCA1, BRCA2, CDK12, ATM, CHEK2, PALB2, or FANCA), whereas DDR-negative (DDR-) patients had no such alterations. Prostate-specific antigen (PSA) response, progression-free survival (PFS, PSA/clinical/radiographic), and overall survival (OS) were assessed in DDR+ and DDR- groups.
Results: Among 129 patients, 81 had DDR+ and 48 had DDR- cancers. A PSA decline of ≥50% was demonstrated in 48% in BRCA, 9% in DDR+ non-BRCA, and 13% in DDR- patients (P < .0001). Objective responses occurred in 37.5% in BRCA, 11% in DDR+ non-BRCA, and 13% in DDR- patients (P = .017). No response was reported in DDR+ patients who had received previous PARPi (n = 16). The median PSA response was 5 months for BRCA, 2 months for DDR+ non-BRCA, and 1.7 months for DDR- patients, respectively (P = .015), whereas the median clinical/radiographic PFS was 4.7 months, 2.8 months, and 2 months, respectively (P = .2). In PARPi-naïve patients, the median OS was 13.7 months for BRCA, 8.7 months for DDR+ non-BRCA, and 6.1 months for DDR- patients (P = .013).
Conclusion: Single-agent platinum agents show significant anticancer activity in BRCA-mutated patients with mCRPC without previous PARPi exposure. With their low cost and broad availability, platinum agents offer a practical alternative, particularly in regions where PARPi are inaccessible.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
